Joch C - Search Results

1

Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study).

Skotnicki A, Lissitchkov TJ, Mamonov V, Buevich E, Kuliczkowski K, Goranov S, Kłoczko J, Klukowska A, Stankovic S, Gercheva L, Chernova T, Hellmann A, Dmoszyńska A, Zawilska K, Veldman A, Joch C, Seifert W. Skotnicki A, et al. Among authors: joch c. Thromb Res. 2016 Jan;137:119-125. doi: 10.1016/j.thromres.2015.10.014. Epub 2015 Oct 13. Thromb Res. 2016. PMID: 26614676 Clinical Trial.

2

Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).

Lissitchkov TJ, Buevich E, Kuliczkowski K, Stasyshyn O, Cerqueira MH, Klukowska A, Joch C, Seifert W. Lissitchkov TJ, et al. Among authors: joch c. Blood Coagul Fibrinolysis. 2017 Mar;28(2):152-162. doi: 10.1097/MBC.0000000000000568. Blood Coagul Fibrinolysis. 2017. PMID: 27203734 Free PMC article.

3

Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers.

Golor G, Bensen-Kennedy D, Haffner S, Easton R, Jung K, Moises T, Lawo JP, Joch C, Veldman A. Golor G, et al. Among authors: joch c. J Thromb Haemost. 2013 Nov;11(11):1977-85. doi: 10.1111/jth.12409. J Thromb Haemost. 2013. PMID: 24112951 Free article. Clinical Trial.

4

Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P).

Dickneite G, Pragst I, Joch C, Bergman GE. Dickneite G, et al. Among authors: joch c. Blood Coagul Fibrinolysis. 2009 Oct;20(7):535-40. doi: 10.1097/MBC.0b013e32832da1c5. Blood Coagul Fibrinolysis. 2009. PMID: 19710609 Review.

5

Safety of Factor XIII Concentrate: Analysis of More than 20 Years of Pharmacovigilance Data.

Solomon C, Korte W, Fries D, Pendrak I, Joch C, Gröner A, Birschmann I. Solomon C, et al. Among authors: joch c. Transfus Med Hemother. 2016 Sep;43(5):365-373. doi: 10.1159/000446813. Epub 2016 Aug 3. Transfus Med Hemother. 2016. PMID: 27781024 Free PMC article.

6

Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency.

Gorkom BL, Holme PA, Joch C, Rogosch T, Feussner A, McKeand W, Roberts J, van Heerde W. Gorkom BL, et al. Among authors: joch c. Hematology. 2020 Dec;25(1):17-25. doi: 10.1080/16078454.2019.1700329. Hematology. 2020. PMID: 31852380 Clinical Trial.

7

Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study.

Hanke AA, Joch C, Görlinger K. Hanke AA, et al. Among authors: joch c. Br J Anaesth. 2013 May;110(5):764-72. doi: 10.1093/bja/aes501. Epub 2013 Jan 18. Br J Anaesth. 2013. PMID: 23335567 Free PMC article. Review.

8

The safety of fibrin sealants.

Joch C. Joch C. Cardiovasc Surg. 2003 Aug;11 Suppl 1:23-8. doi: 10.1016/S0967-2109(03)00068-1. Cardiovasc Surg. 2003. PMID: 12869985

9

[Safety of plasma-derived factor concentrates: an example of pharmacovigilance with fibrinogen and factor XIII-concentrate].

Spannagl M, Joch Ch, Heindl B. Spannagl M, et al. Among authors: joch ch. Hamostaseologie. 2006 Aug;26(3 Suppl 1):S36-40. Hamostaseologie. 2006. PMID: 16953291 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9 results

Search Page